Dec 12, 2025
Quanex Building Products Corporation (NYSE:NX) is a key player in the building products industry, specializing in the manufacture of engineered products for the window and door industry. The company operates within the Zacks Building Products - Miscellaneous industry and has been making significant strides in its financial performance. NX's recent earnings report has caught the attention of investors, leading to a notable surge in its stock price.
On December 11, 2025, NX reported earnings per share (EPS) of $0.83, significantly surpassing the estimated $0.50. This impressive performance marks a 66% earnings surprise, as highlighted by Zacks. Compared to the same quarter last year, where EPS was $0.61, NX has shown substantial growth. Despite a previous quarter's negative surprise of 18.82%, NX has exceeded consensus EPS estimates in three of the last four quarters.
In terms of revenue, NX achieved approximately $489.8 million, exceeding the estimated $470.7 million by 3.78%. Although slightly lower than the $492.16 million reported in the same period last year, NX has consistently outperformed consensus revenue estimates over the past four quarters. This consistent performance underscores the company's ability to deliver strong financial results.
NX's financial health is further supported by a significant net sales growth of approximately 44% year-over-year for the fiscal year ending October 31, 2025. The company successfully repaid $75 million of debt, enhancing its balance sheet. Cash provided by operating activities increased by about 86%, indicating strong liquidity. The integration of the transformative acquisition, Tyman, is substantially complete, aligning with NX's strategic objectives.
NX maintains a strong liquidity position with a current ratio of approximately 2.04. The company's debt-to-equity ratio of about 1.18 indicates a significant use of debt financing relative to equity. These financial metrics, combined with the successful integration of Tyman, position NX well for future growth and stability in the building products industry.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a company involved in the development and commercialization of diagnostic medi...
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company known for its work in developing mRNA-based vaccines and therape...